At Johnson & Johnson, we are working toward a world where a healthy mind, body, and environment is within reach for everyone, everywhere. While significant progress has been made to improve the health and well-being of individuals, families and communities in under-served regions around the world, major challenges with both infectious and chronic diseases persist. One important driver, particularly for infectious diseases, is the connection between human health and the health of the environment. This critical inter-relationship underscores our efforts to address challenges presented by climate change, which has a major effect on the spread of disease. One important driver, particularly for infectious diseases, is the connection between human health and the health of the environment. This critical interrelationship underscores our efforts to address challenges presented by climate change, which has a major effect on the spread of disease.
At Johnson & Johnson Global Public Health we seek to overcome intractable global health challenges.
Critical global public health challenges such as multidrug-resistant tuberculosis (MDR-TB), HIV, mental health and others seek new leadership, new ideas, and faster ways of delivering impact. As one of the world’s largest health care companies, Johnson & Johnson has a legacy of combining innovation, science, and ingenuity to tackle some of the most pressing public health challenges of the day.
Building on that foundation, we established our enterprise-wide Global Public Health (GPH) organization to redefine what it means to do business in low-resource settings. This team is working to form unconventional partnerships and accelerate the pace of innovation needed to broaden our reach and deepen our impact.
Leveraging the resources, capabilities, and competitive spirit that have helped Johnson & Johnson bring good health to a billion people every day, GPH has set big goals. Working with those directly impacted, we aim to make MDR-TB and HIV history, and to wrestle with several other public health challenges.
The idea is not only to discover and develop products, and make them affordable, but also to get traction on how these products will reach and measurably improve the health of patients who need them.
GPH senior leadership includes representatives from our Consumer, Medical Devices, Pharmaceutical and Vision Care business segments, as well as Corporate Affairs (Communications, Corporate Equity and Global Community Impact), Worldwide Government Affairs & Policy, Finance, and Human Resources. Oversight is provided by members of the Johnson & Johnson Executive Committee.
Our Health for Humanity 2020 Goals include GPH initiatives to develop a long-acting HIV regimen with EDURANT® (rilpivirine) and to expand the database documenting SIRTURO® (bedaquiline) effectiveness, efficacy and safety profile through collaborative efforts to further increase access. You can also learn more about our efforts to advance the health and well-being of women and children through 2020 Goals dedicated to training skilled birth attendants and supporting improvements in youth eye health.
In April we announced the official launch of Johnson & Johnson's global public health strategy at the opening of on-the-ground global public health operations in Cape Town, South Africa. The goal of the new Operations Center is to work in close partnership with local governments and NGOs on the ground to help get the most innovative treatments for such diseases as HIV and multidrug-resistant tuberculosis to the people who need them the most, as well as develop programs designed to improve access to health care for vulnerable communities throughout Africa.
We brought our HIV expertise and our consumer human-centered design and research capabilities to DREAMS, an ambitious partnership among the U.S. President's Emergency Plan for AIDS Relief program, the Bill & Melinda Gates Foundation, Johnson & Johnson and others to reduce new HIV infections in adolescent girls and young women by 40 percent in 10 sub-Saharan African countries by 2017.
Working with public and private partners, we implemented programs to prevent and detect Zika cases, and to provide appropriate care to infected pregnant women.
We joined more than 80 companies and organizations in signing the Declaration on Combating Antimicrobial Resistance at the 2016 World Economic Forum in Davos. Building on this commitment, Johnson & Johnson joined 12 pharmaceutical companies in presenting a roadmap that lays out four key commitments they will deliver by 2020 to reduce antimicrobial resistance.
After a priority review by the U.S. Food and Drug Administration (FDA), Janssen received approval for VERMOXTM CHEWABLE (mebendazole chewable 500mg tablets) to treat roundworm and whipworm in younger children (≥1 yr old). This approval addresses an unmet need for children too young to swallow a solid tablet. For more information on our goal to address intestinal parasitic infections, see our Health for Humanity 2020 Goals Progress Scorecard.
CaringCrowd®, our public health crowd funding program, brings together project owners to find donors and people who want to support global public health. In this first full year of the initiative, the program funded 21 projects from nonprofit organizations.
In partnership with companies representing a broad array of industry sectors, we advanced the Global Health Security Agenda Private Sector Roundtable into a functional coalition, which will work to mobilize industry, NGOs, multilateral institutions and governments to help countries prevent, detect and respond to health-related crises, and strengthen systems for health security.